iBio vs Rallybio
IBIO and RLYB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IBIO and RLYB compare
Rallybio is the larger company, worth 1.8 times as much as iBio ($84.6M against $47.1M).
iBio grew revenue faster over the last twelve months (115% versus −35.6% for Rallybio).
Rallybio keeps more of each dollar of sales as profit, with a net margin of 6177% compared with −3244% at iBio.
Rallybio scores higher on the StockData Score (10 against 9 for iBio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IBIO | RLYB |
|---|---|---|
| Size and price | ||
| Market cap | $47.1M | $84.6M |
| Share price | $0.732 | $15.72 |
| Change, 1 year | −41.5% | 181% |
| Change, 5 years | −99.8% | −85.5% |
| Beta (5Y) | 1.12 | 0.64 |
| Employees | 23 | 14 |
| StockData Score | ||
| Total score | 9 | 10 (better) |
| Valuation score | 1 | 2 (better) |
| Growth score | 1 (better) | 0 |
| Performance score | 2 | 2 |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 3.4× |
| P/S | 43.8× (better) | 195× |
| P/B | 0.6× (better) | 0.9× |
| FCF yield | −58.6% | – |
| Growth | ||
| Revenue growth (TTM) | 115% (better) | −35.6% |
| Revenue growth, 5Y average | −46.9% | – |
| Profitability | ||
| Operating margin | −3491% (better) | −5581% |
| Net margin | −3244% | 6177% (better) |
| FCF margin | −2566% | – |
| Return on equity | −51.8% | 34.5% (better) |
| Return on invested capital | −728% | −718% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 9.48 | 28.87 (better) |
| Altman Z-score | −3.49 | 11.84 (better) |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 54.0% | – |
| Held by insiders | 0.47% | 72.6% |
| Insider net buying, 12 months | $98.1K | $4.2M (better) |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 6.3% | 2.6% |
Go deeper
- IBIO stock overview
- IBIO income statement
- IBIO valuation and score
- RLYB stock overview
- RLYB income statement
- RLYB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.